Profile
John Nicholas Lambert is the founder of Cryptopharma Pty Ltd.
founded in 2000.
He worked as a Chief Executive Officer, Director & MD at Amplia Therapeutics Ltd.
from 2020 to 2022.
He was a Principal Director-Product Development Operations at Biota Holdings Pty Ltd.
from 2011 to 2013.
He worked as a Research Director-US Operations at Biota, Inc. He was a Senior Director at Medicines Development for Global Health Ltd from 2016 to 2020.
He also worked as a Senior Lecturer at the University of Melbourne and as a Vice President-Product Development & Operations at Aviragen Therapeutics, Inc. Dr. Lambert holds a doctorate degree from the University of Melbourne.
Former positions of John Nicholas Lambert
| Companies | Position | End |
|---|---|---|
| AMPLIA THERAPEUTICS LIMITED | Chief Executive Officer | 2022-12-04 |
Medicines Development for Global Health Ltd
 Medicines Development for Global Health Ltd Pharmaceuticals: MajorHealth Technology Medicines Development Ltd. engages in the development of medicines and vaccines. Its development programs include Moxidectin Program, Global Health Programs, and Consulting ervices. The company was founded by Mark Sullivan in 2005 and is headquartered in Melbourne, Australia. | Director/Board Member | 2020-08-31 |
Cryptopharma Pty Ltd.
 Cryptopharma Pty Ltd. Medical SpecialtiesHealth Technology Cryptopharma Pty Ltd. develops novel anti-inflammatory therapeutic agents for the treatment of pulmonary diseases. It focuses on the development of CP92, a treatment of Cystic Fibrosis. The company was founded by Alastair George Stewart and John Lambert in October 2000 and is headquartered in Victoria, Australia. | Founder | 2011-05-03 |
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Chief Operating Officer | - |
University of Melbourne
 University of Melbourne Other Consumer ServicesConsumer Services The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs. | Corporate Officer/Principal | - |
Training of John Nicholas Lambert
| University of Melbourne | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| AMPLIA THERAPEUTICS LIMITED | Health Technology |
| Private companies | 5 |
|---|---|
Biota Holdings Pty Ltd.
 Biota Holdings Pty Ltd. Pharmaceuticals: MajorHealth Technology Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. | Health Technology |
Cryptopharma Pty Ltd.
Cryptopharma Pty Ltd. Medical SpecialtiesHealth Technology Cryptopharma Pty Ltd. develops novel anti-inflammatory therapeutic agents for the treatment of pulmonary diseases. It focuses on the development of CP92, a treatment of Cystic Fibrosis. The company was founded by Alastair George Stewart and John Lambert in October 2000 and is headquartered in Victoria, Australia. | Health Technology |
| Biota, Inc. | |
Medicines Development for Global Health Ltd
Medicines Development for Global Health Ltd Pharmaceuticals: MajorHealth Technology Medicines Development Ltd. engages in the development of medicines and vaccines. Its development programs include Moxidectin Program, Global Health Programs, and Consulting ervices. The company was founded by Mark Sullivan in 2005 and is headquartered in Melbourne, Australia. | Health Technology |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
- Stock Market
- Insiders
- John Nicholas Lambert
